Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TauTX
- Development stage
- Unknown
- Lead developer
- TauRx Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TauTX is a small molecule modulator designed to target tau protein aggregation. It was developed by Chord Therapeutics, a company focused on rare neurological disorders, and was in Phase 1 development for progressive supranuclear palsy and other tauopathies. Merck KGaA acquired Chord Therapeutics, integrating TauTX into its neurology pipeline to address unmet needs in rare diseases.
02
Targets
Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on TauTX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TauTX.